New drug danicopan under Real-World review for rare blood disorder
NCT ID NCT07457151
First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This study tracks 8 Korean patients with paroxysmal nocturnal hemoglobinuria (PNH) who are taking Danicopan alongside standard C5 inhibitors like eculizumab or ravulizumab. The goal is to monitor safety and check if the drug works as expected in everyday medical practice. It is a post-marketing commitment required by Korean health authorities.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Danicopan
What this could lead to
If successful, this study will confirm that Danicopan is safe and effective for controlling PNH when used alongside standard treatments in real-world settings.
What could go wrong
This is a small, observational post-marketing study with only 8 participants, so results may not apply broadly. It is designed to monitor known risks, not to prove new benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGHwasun-gun, South Korea
-
Research Site
RECRUITINGSeoul, South Korea